410 Medical Presents LifeFlow® Simulation Data at ACEP17

Oct 31, 2017 |

-LifeFlow Improves Speed and Efficiency in Septic Shock Resuscitation-

DURHAM, N.C., October 31, 2017 — 410 Medical, Inc., a medical device company focused on developing innovative technologies for fluid resuscitation of critically ill patients, presented LifeFlow® simulation data at the annual scientific assembly of the American College of Emergency Physicians, ACEP17, the largest emergency medicine conference in the world.

410 Medical Co-founder and Chief Medical Officer, Dr. Mark Piehl, presented the abstract “A Novel Technique for Improving Fluid Resuscitation in Septic Shock” during the ACEP17 Research Forum (abstract 383). The goal of the study was to compare 410 Medical’s LifeFlow Rapid Infuser to pressure bag for administering fluid boluses in simulated pre-hospital and hospital settings.

In this study, individual providers were asked to perform all elements of care in the initial resuscitation of a simulated septic shock patient, including the delivery of 500ml normal saline boluses to normalize blood pressure. The scenario was predetermined to require three fluid boluses to achieve systolic blood pressure (SBP) greater than 90 mmHg. Fourteen paramedics and registered nurses (RN) were randomized to LifeFlow or pressure bag for the fluid delivery technique. The results presented are as follows:

  •  Total time to completion of the sepsis scenario was almost twice as fast for the LifeFlow device compared to pressure bag (20 versus 36 minutes)
  •  Time to completion of each bolus was three times as fast for LifeFlow compared to pressure bag (2.5 versus 7.6 minutes)
  •  Accuracy of fluid volume delivered was greater with LifeFlow, with significantly less variance in fluid volume administered using LifeFlow device compared to pressure bag infusion (39 ml versus 184 ml)

“Fluid resuscitation is an essential component of care in the treatment of septic shock, but current methods are often slow and inefficient, leading to difficulty meeting fluid delivery targets,” stated Dr. Mark Piehl, 410 Medical Co-founder and Chief Medical Officer. “This study demonstrates that LifeFlow can significantly improve the speed, efficiency and accuracy of fluid resuscitation, helping clinicians provide better patient care and successfully adhere to sepsis protocols.”LifeFlow was cleared by the FDA for use in 2016 and is currently available throughout the United States.

About 410 Medical, Inc.

Founded in 2013, 410 Medical is a medical device company dedicated to developing innovative products that enable frontline medical providers to improve care for critically ill patients. 410 Medical’s first product, LifeFlow®, is designed to enhance the speed and efficiency of fluid resuscitation, improving care for patients with life-threatening illnesses such as sepsis and shock. LifeFlow was cleared by the FDA for human use in 2016. For more information, visit www.410medical.com.

Media Contact:

Michael Parks